Editor’s Choice for May 2018

The 2018 Myeloma Knowledge Exchange

The evolution of imaging techniques for multiple myeloma

Diagnosis and management of smouldering myeloma

Clinical management of plasma cell leukaemia

Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099

A variety of approaches to measure the efficacy of PARP inhibitors

Development and clinical indications of PARP inhibitors

First-in-human trial results of RET targeted BLU-667

Treating RET alterations with novel therapy BLU-667

Increasing diversity through the NCI SBIR development centre